Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial - Ahmann, Andrew J.; Capehorn, Matthew; Charpentier, Guillaume; Dotta, Francesco; Henkel, Elena; Lingvay, Ildiko; Holst, Anders G.; Annett, Miriam P.; Aroda, Vanita R. (Diabetes care, 2018)
Keywords: Adult; Aged; Aged, 80 and over; Antidiabetics; Blood Glucose - drug effects; Blood Glucose - metabolism; Body weight; Body Weight - drug effects; Clinical trials; Delayed-Action Preparations - administration & dosage; Delayed-Action Preparations - adverse effects; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Drug Administration Schedule; Drug therapy; Drugs; Evidence-based medicine; Exenatide; Female; Glucagon-Like Peptides - administration & dosage; Glucagon-Like Peptides - adverse effects; Glucose monitoring; Glycated Hemoglobin A - drug effects; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - adverse effects; Male; Metformin - administration & dosage; Middle Aged; Peptides - administration & dosage; Peptides - adverse effects; Research design; Safety; Treatment Outcome; Venoms - administration & dosage; Venoms - adverse effects; Weight reduction; Young Adult